SVCM
JAZZ icon

Saturn V Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Saturn V Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.8M Sell
162,961
-85,109
-34% -$14.9M 5.58% 8
2025
Q4 		$42.2M Sell
248,070
-52,540
-17% -$8.05M 7.74% 4
2025
Q3 		$39.6M Buy
300,610
+93,658
+45% +$11.2M 8.69% 3
2025
Q2 		$22M Buy
+206,952
New +$22.5M 8.9% 1

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Saturn V Capital Management's JAZZ Position: Q1 2026 in Review

Saturn V Capital Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 34% in Q1 2026, selling an estimated $14.9M and leaving 162,961 shares worth $30.8M. The position accounts for 5.58% of the portfolio, ranked #8.

Saturn V Capital Management first reported a position in JAZZ in Q2 2025 and has held it in 4 quarters since. The position peaked at $42.2M in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Saturn V Capital Management held 162,961 shares of Jazz Pharmaceuticals worth $30.8M as of Q1 2026.
  • Saturn V Capital Management sold 85,109 Jazz Pharmaceuticals shares in Q1 2026, an estimated $14.9M.
  • Jazz Pharmaceuticals made up 5.58% of Saturn V Capital Management's portfolio in Q1 2026, its #8 holding.
  • Saturn V Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Saturn V Capital Management's Jazz Pharmaceuticals position peaked at $42.2M in Q4 2025.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Saturn V Capital Management's 13F filing for Q1 2026, filed 15 May 2026.